Want to see TSE:EXE full AI Analyst Report?
Earnings Data
Report Date
Aug 06, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
0.4Last Year’s EPS
0.37Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed strong operational and financial momentum driven by robust home health organic growth, margin expansion across segments, successful midyear acquisitions performing ahead of expectations, a strategic accretive CBI transaction, improved liquidity and a dividend increase. Identified challenges were largely manageable and relate to integration execution, lumpy out-of-period items, localized labor constraints in rural markets, some managed services revenue loss following third-party contract terminations, higher maintenance CapEx timing and modest dilution from an equity raise. Overall, positives (notably large percentage increases in EBITDA, revenue growth, home health volume and margin gains, and strategic M&A) materially outweigh the headwinds.Company Guidance
Strong Adjusted EBITDA Growth
Q4 adjusted EBITDA of $45.6 million, an increase of 36.4% year-over-year (after adjusting for out-of-period items); consolidated Q4 NOI improved by $14.3 million or 30.2% (ex-out-of-period).
Robust Home Health (ParaMed) Expansion
ParaMed delivered 15.3% organic volume growth in Q4; home health Q4 revenue rose 33.6% year-over-year (up $49.7 million) driven by Closing the Gap contribution and organic growth; home health NOI margins improved 280 basis points to 13.2% (ex-out-of-period).
Long-Term Care Margin Improvement and High Occupancy
Long-term care NOI margins increased 90 basis points to 10.9% in Q4 (ex-out-of-period items); occupancy remained strong at 98%.
Successful Acquisitions Performing Ahead of Pro Forma
Integration of Revera-acquired LTC homes complete; Closing the Gap integration underway and performing ahead of pro forma expectations; combined acquisitions contributed approximately $61.8 million in revenue to Q4.
Major Strategic CBI Home Health Transaction
Agreement to acquire CBI Home Health for $570 million expected to add ~10 million hours, ~8,500 team members, ~$478 million in revenue and ~$61.9 million in pro forma adjusted EBITDA; transaction initially 9% accretive to EPS, rising to 15% when $7.4 million of synergies are realized; regulatory approvals progressing.
Improved Liquidity and Financing Execution
Completed $200 million bought deal private placement (net proceeds $191.5 million); secured $214.5 million senior secured credit facility expansion; year-end cash on hand $348 million and $154 million available lines of credit; planned financing expected to result in pro forma total debt/adjusted EBITDA of ~2.7–2.9x at CBI close.
Dividend Increase Reflects Financial Strength
Announced a 5% increase to the monthly dividend to $0.0441, the second consecutive annual increase; Q4 payout ratio 42% and full-year 46% (both adjusted for out-of-period items).
Redevelopment Pipeline and Asset Recycling
Commenced preliminary construction on a 320-bed Sudbury home; 7 homes under construction with total investment of $692.3 million; sale of vacated West End Villa generated $12.5 million proceeds and $10.1 million after-tax gain to recycle capital into redevelopment pipeline.
Managed Services Scale and Margins
Third-party and JV beds served by SGP grew to over 153,500 (up 5% YoY); managed services NOI margins at 55.5%, in line with long-term expectations (50%–55%).
Affirmation of AFFO Improvement (Excluding Items)
When excluding out-of-period items, AFFO per basic share improved 6% year-over-year to $0.301 per share, indicating underlying cash generation improvement.
TSE:EXE Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
TSE:EXE Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2026 | C$30.12 | C$33.35 | +10.73% |
Feb 26, 2026 | C$23.97 | C$26.43 | +10.26% |
Nov 11, 2025 | C$15.73 | C$18.20 | +15.68% |
Aug 06, 2025 | C$12.41 | C$12.38 | -0.24% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Extendicare (TSE:EXE) report earnings?
Extendicare (TSE:EXE) is schdueled to report earning on Aug 06, 2026, After Close (Confirmed).
What is Extendicare (TSE:EXE) earnings time?
Extendicare (TSE:EXE) earnings time is at Aug 06, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TSE:EXE EPS forecast?
TSE:EXE EPS forecast for the fiscal quarter 2026 (Q2) is 0.4.